Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for advanced gastric cancer (JCOG1013, GC_CS/DCS_P3 ADOPT)

Trial Profile

Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for advanced gastric cancer (JCOG1013, GC_CS/DCS_P3 ADOPT)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 May 2016

At a glance

  • Drugs Docetaxel (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Acronyms ADOPT
  • Most Recent Events

    • 30 Mar 2016 Status changed from recruiting to active, no longer recruiting.
    • 12 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top